Tafazzin (TAZ) (Middle Region) Peptid
-
- Target Alle TAZ Produkte
- TAZ (Tafazzin (TAZ))
- Protein Region
- Middle Region
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Sequenz
- LHSHFFSLGK CVPVCRGAEF FQAENEGKGV LDTGRHMPGA GKRREKGDGV
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-TAZ Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- TAZ (Tafazzin (TAZ))
- Hintergrund
-
This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced, the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known.
Alias Symbols: TAZ,EFE2,G4.5,
Protein Size: 292 - Gen-ID
- 6901
- UniProt
- Q16635
-